Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Atezolizumab Gets CDF Place For Bladder Cancer

Executive Summary

Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.

You may also be interested in...



NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund

Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route. 

Imfinzi EU Bladder Cancer Filing On Back Burner As AZ Focuses On Lung

The CHMP decided against an accelerated review of Imfinzi in both bladder and lung cancer but unlike in the case of NSCLC, AstraZeneca has not filed for the former indication.

Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial

A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel